Analysed CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) News Sources
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
15-03-2026
marketbeat.com
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth
19-04-2026
yahoo.com
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
08-05-2026
yahoo.com
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
22-05-2026
marketbeat.com
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
25-05-2026
yahoo.com
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
01-06-2026
yahoo.com
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
30-06-2026
yahoo.com
What is the current price of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)?
The current price of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) is $15.19.
CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) absolute price change since previous trading day?
The absolute price change of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) since the previous trading day is $-0.26.
CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) percentage price change since previous trading day?
The percentage price change of CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) since the previous trading day is -1.6828%.
What is the most recent average sentiment score for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)?
The most recent average sentiment score for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)?
The most recent sentiment for CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ) is .
SEC-8K** Filing Available For CONTINEUM THERAPEUTICS INC-A (CTNM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.